tetano
Editor, Senior Moderator
Sci Rep
. 2024 Apr 11;14(1):8472.
doi: 10.1038/s41598-024-52810-0. An RNA-hydrolyzing recombinant minibody prevents both influenza A virus and coronavirus in co-infection models
Quynh Xuan Thi Luong[SUP] 1 [/SUP], Phuong Thi Hoang[SUP] 1 [/SUP], Yongjun Lee[SUP] 1 [/SUP], Ramadhani Qurrota Ayun[SUP] 1 [/SUP], Kyungho Na[SUP] 1 [/SUP], Seonhyeon Park[SUP] 1 [/SUP], Chengmin Lin[SUP] 1 [/SUP], Phuong Thi Ho[SUP] 1 [/SUP], Taek-Kyun Lee[SUP] 2 [/SUP], Sukchan Lee[SUP] 3 [/SUP]
Affiliations
With the lifting of COVID-19 non-pharmaceutical interventions, the resurgence of common viral respiratory infections was recorded in several countries worldwide. It facilitates viral co-infection, further burdens the already over-stretched healthcare systems. Racing to find co-infection-associated efficacy therapeutic agents need to be rapidly established. However, it has encountered numerous challenges that necessitate careful investigation. Here, we introduce a potential recombinant minibody-associated treatment, 3D8 single chain variable fragment (scFv), which has been developed as a broad-spectrum antiviral drug that acts via its nucleic acid catalytic and cell penetration abilities. In this research, we demonstrated that 3D8 scFv exerted antiviral activity simultaneously against both influenza A viruses (IAVs) and coronaviruses in three established co-infection models comprising two types of coronaviruses [beta coronavirus-human coronavirus OC43 (hCoV-OC43) and alpha coronavirus-porcine epidemic diarrhea virus (PEDV)] in Vero E6 cells, two IAVs [A/Puerto Rico/8/1934 H1N1 (H1N1/PR8) and A/X-31 (H3N2/X-31)] in MDCK cells, and a combination of coronavirus and IAV (hCoV-OC43 and adapted-H1N1) in Vero E6 cells by a statistically significant reduction in viral gene expression, proteins level, and approximately around 85%, 65%, and 80% of the progeny of 'hCoV-OC43-PEDV', 'H1N1/PR8-H3N2/X-31', and 'hCoV-OC43-adapted-H1N1', respectively, were decimated in the presence of 3D8 scFv. Taken together, we propose that 3D8 scFv is a promising broad-spectrum drug for treatment against RNA viruses in co-infection.
. 2024 Apr 11;14(1):8472.
doi: 10.1038/s41598-024-52810-0. An RNA-hydrolyzing recombinant minibody prevents both influenza A virus and coronavirus in co-infection models
Quynh Xuan Thi Luong[SUP] 1 [/SUP], Phuong Thi Hoang[SUP] 1 [/SUP], Yongjun Lee[SUP] 1 [/SUP], Ramadhani Qurrota Ayun[SUP] 1 [/SUP], Kyungho Na[SUP] 1 [/SUP], Seonhyeon Park[SUP] 1 [/SUP], Chengmin Lin[SUP] 1 [/SUP], Phuong Thi Ho[SUP] 1 [/SUP], Taek-Kyun Lee[SUP] 2 [/SUP], Sukchan Lee[SUP] 3 [/SUP]
Affiliations
- PMID: 38605110
- DOI: 10.1038/s41598-024-52810-0
With the lifting of COVID-19 non-pharmaceutical interventions, the resurgence of common viral respiratory infections was recorded in several countries worldwide. It facilitates viral co-infection, further burdens the already over-stretched healthcare systems. Racing to find co-infection-associated efficacy therapeutic agents need to be rapidly established. However, it has encountered numerous challenges that necessitate careful investigation. Here, we introduce a potential recombinant minibody-associated treatment, 3D8 single chain variable fragment (scFv), which has been developed as a broad-spectrum antiviral drug that acts via its nucleic acid catalytic and cell penetration abilities. In this research, we demonstrated that 3D8 scFv exerted antiviral activity simultaneously against both influenza A viruses (IAVs) and coronaviruses in three established co-infection models comprising two types of coronaviruses [beta coronavirus-human coronavirus OC43 (hCoV-OC43) and alpha coronavirus-porcine epidemic diarrhea virus (PEDV)] in Vero E6 cells, two IAVs [A/Puerto Rico/8/1934 H1N1 (H1N1/PR8) and A/X-31 (H3N2/X-31)] in MDCK cells, and a combination of coronavirus and IAV (hCoV-OC43 and adapted-H1N1) in Vero E6 cells by a statistically significant reduction in viral gene expression, proteins level, and approximately around 85%, 65%, and 80% of the progeny of 'hCoV-OC43-PEDV', 'H1N1/PR8-H3N2/X-31', and 'hCoV-OC43-adapted-H1N1', respectively, were decimated in the presence of 3D8 scFv. Taken together, we propose that 3D8 scFv is a promising broad-spectrum drug for treatment against RNA viruses in co-infection.